RxDoctor Payments Data

Alexander Moore, MD

Family Medicine · Atlanta, GANPI 1619062155

Payments from drug & device makers

$6,766in general payments, 2019–2025

Across 393 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Antares Pharma, Inc.$790
  • AstraZeneca$671
  • Lilly USA, LLC$421
  • Amgen$399
  • Boehringer Ingelheim$284
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$6,72899%
  • Education$381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,766 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$98,206
Medicare patients
267
Services billed
2,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$142,970
FarxigaDapagliflozin Propanediol81$92,392
JardianceEmpagliflozin72$71,297
Repatha SureclickEvolocumab53$52,890
MounjaroTirzepatide38$45,993
EliquisApixaban46$43,040
OmnitropeSomatropin16$40,107
MyrbetriqMirabegron51$39,747
XareltoRivaroxaban13$19,588
TrulicityDulaglutide11$16,132
TradjentaLinagliptin13$12,227
Tresiba Flextouch U-100Insulin Degludec17$8,539
Testosterone22$5,893
SynthroidLevothyroxine Sodium30$3,752
Rosuvastatin Calcium269$3,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,363$142,970107 claims
AstraZenecaFarxiga$671$92,39281 claims
Boehringer IngelheimJardiance, Tradjenta$284$83,52585 claims
Lilly USA, LLCMounjaro, Trulicity$421$62,12549 claims
PfizerEliquis$84$43,04046 claims
Astellas Pharma US IncMyrbetriq$16$39,74751 claims
Johnson & JohnsonXarelto$41$19,58813 claims
AbbVieSynthroid, Armour Thyroid$84$5,47842 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →